This Is MS Multiple Sclerosis Knowledge & Support Community

Very interesting report. I guess in case of younger patients and early use the results would be even much better. http://www.medscape.com/viewarticle/712607 IMHO one reason not to follow up with this is, that the manufacturer dont want to compete with his own more expensive monoclonals. It´s sorry t...

If there is a project looking for financial support and its proposed mechanism of action is in clear contradiction with evidence based and generally accepted medical knowledge, then one has to ask first, maybe this is just a project for profit only? I am not against innovative and aggressive new tre...